Studies on immunotherapy targeting immune checkpoint (i.e., cytotoxic T-lymphocyte-associated antigen 4 and programmed death 1 receptor) have raised the prospect that the immune system may represent a favorable approach for advancing the treatment of CRC [43, 44]. Here, CTLA4 is linked to colorectal carcinoma.